Table III.
Efficacy of Olmesartan Medoxomil (OM) and OM/HCTZ in Subpopulations of Patients Based on the Results of a Post Hoc Analysis
| Subpopulation/Efficacy Measure, mm Hg | OM 20 mg/d | OM 40 mg/d | OM/HCTZ 40/12.5 mg/d | OM/HCTZ 40/25 mg/d |
|---|---|---|---|---|
| Age | ||||
| <65 y, No. | 109 | 104 | 101 | 93 |
| Baseline SBP/DBP, mean | 169.5/97.4 | 169.5/97.4 | 169.4/97.4 | 169.5/97.4 |
| ΔSBP, mean (SD)* | −17.7 (14.7)† | −19.0 (15.6)† | −31.3 (14.9)† | −33.2 (13.9)† |
| ΔDBP, mean (SD)* | −6.5 (8.1)† | −7.3 (8.1)† | −13.0 (9.0)† | −14.0 (9.0)† |
| BP <140/90, %‡; | 17.4 | 33.9 | 61.5 | 75.2 |
| ≥65 y, No. | 60 | 56 | 56 | 50 |
| Baseline SBP/DBP, mean | 174.7/91.0 | 174.7/91.6 | 174.9/91.8 | 174.9/92.7 |
| ΔSBP, mean (SD)* | −15.5 (13.6)† | −17.2 (14.7)† | −28.7 (15.1)† | −37.0 (15.2)† |
| ΔDBP, mean (SD)* | −3.7 (8.7)§ | −5.9 (6.8)† | −8.8 (8.5)† | −13.1 (8.8)† |
| BP <140/90, %‡; | 11.7 | 20.0 | 45.0 | 61.7 |
| ISH | ||||
| ISH, No. | 41 | 37 | 37 | 32 |
| Baseline SBP, mean | 173.1 | 173.0 | 173.3 | 172.9 |
| ΔSBP, mean (SD)* | −17.7 (16.0)† | −17.7 (15.0)† | −29.6 (14.8)† | −36.4 (13.7)† |
| SBP <140, %‡; | 17.1 | 26.8 | 56.1 | 68.3 |
| Non‐ISH, No. | 128 | 123 | 120 | 111 |
| Baseline SBP, mean | 170.8 | 170.8 | 170.8 | 170.9 |
| ΔSBP, mean (SD)* | −16.6 (13.8)† | −18.6 (15.4)† | −30.6 (15.1)† | −34.0 (14.6)† |
| SBP <140, %‡; | 18.0 | 32.0 | 58.6 | 77.3 |
| Race | ||||
| Nonblack, No. | 143 | 134 | 131 | 118 |
| Baseline SBP/DBP, mean | 171.4/94.4 | 171.3/94.6 | 171.4/94.6 | 171.4/95.0 |
| ΔSBP, mean (SD)* | −18.3 (13.9)† | −20.2 (13.8)† | −30.5 (15.2)† | −35.1 (14.6)† |
| ΔDBP, mean (SD)* | −5.9 (8.5)† | −7.3 (7.4)† | −11.2 (9.3)† | −13.7 (8.5)† |
| BP <140/90, %‡; | 16.8 | 30.8 | 55.9 | 72.7 |
| Black, No. | 26 | 26 | 26 | 25 |
| Baseline SBP/DBP, mean | 171.3/99.4 | 171.3/99.4 | 171.3/99.4 | 171.3/99.1 |
| ΔSBP, mean (SD)* | −9.0 (14.0)|| | −9.0 (18.8)¶ | −29.4 (14.1)† | −32.0 (13.5)† |
| ΔDBP, mean (SD)* | −3.5 (7.7) ¶ | −4.3 (8.6) ¶ | −13.0 (7.9)† | −13.4 (10.8)† |
| BP <140/90, %‡; | 7.7 | 19.2 | 53.8 | 57.7 |
| Sex | ||||
| Men, No. | 78 | 75 | 75 | 65 |
| Baseline SBP/DBP, mean | 170.8/96.7 | 170.9/96.8 | 170.9/96.8 | 171.4/97.2 |
| ΔSBP, mean (SD)* | −15.9 (14.0)† | −20.3 (13.2)† | −29.0 (14.6)† | −32.2 (14.1)† |
| ΔDBP, mean (SD)* | −6.6 (8.0)† | −8.7 (7.1)† | −12.4 (8.5)† | −13.9 (8.1)† |
| BP <140/90, %‡; | 12.8 | 26.9 | 53.8 | 71.8 |
| Women, No. | 91 | 85 | 82 | 78 |
| Baseline SBP/DBP, mean | 171.8/93.9 | 171.7/94.2 | 171.8/94.1 | 171.3/94.5 |
| ΔSBP, mean (SD)* | −17.7 (14.6)† | −16.7 (16.8)† | −31.6 (15.3)† | −36.5 (14.4)† |
| ΔDBP, mean (SD)* | −4.6 (8.7)† | −5.2 (7.8)† | −10.6 (9.5)† | −13.5 (9.6)† |
| BP <140/90, %‡; | 17.6 | 30.8 | 57.1 | 69.2 |
| BMI | ||||
| <25 kg/m2, No. | 21 | 19 | 18 | 15 |
| Baseline SBP/DBP, mean | 172.5/92.9 | 172.7/92.3 | 173.1/91.8 | 172.4/93.9 |
| ΔSBP, mean (SD)* | −17.0 (14.4)† | −17.5 (17.3)† | −29.2 (18.4)† | −31.3 (16.1)† |
| ΔDBP, mean (SD)* | −6.7 (8.1)† | −6.1 (9.6) ¶ | −10.0 (12.7) ¶ | −12.8 (12.1)† |
| BP <140/90, %‡; | 19.0 | 23.8 | 57.1 | 66.7 |
| 25–29 kg/m2, No. | 61 | 56 | 56 | 54 |
| Baseline SBP/DBP, mean | 171.5/94.6 | 171.2/95.4 | 171.2/95.4 | 171.3/95.1 |
| ΔSBP, mean (SD)* | −17.0 (14.4)† | −19.8 (14.6)† | −29.4 (15.6)† | −36.6 (14.0)† |
| ΔDBP, mean (SD)* | −5.4 (8.2)† | −7.0 (7.0)† | −11.8 (9.3)† | −14.5 (7.3)† |
| BP <140/90, %‡; | 16.4 | 31.1 | 55.7 | 72.1 |
| ≥30 kg/m2, No. | 86 | 84 | 82 | 73 |
| Baseline SBP/DBP, mean | 171.0/96.0 | 171.1/96.0 | 171.1/96.1 | 171.2/96.4 |
| ΔSBP, mean (SD)* | −17.0 (14.3)† | −18.1 (14.9)† | −31.4 (13.8)† | −33.8 (14.5)† |
| ΔDBP, mean (SD)* | −5.3 (8.7)† | −6.8 (7.7)† | −11.7 (8.0)† | −13.1 (9.4)† |
| BP <140/90, %‡; | 14.0 | 29.1 | 55.8 | 70.9 |
| Last observation carried forward. †P<.001 vs baseline. ‡Cumulative (percentage of the total number of patients in the efficacy cohort in each subpopulation). §P<.005 vs baseline. ||P<.01 vs baseline. ¶P<.05 vs baseline. HCTZ indicates hydrochlorothiazide; SBP, systolic blood pressure (BP); DBP, diastolic BP; Δ, change; ISH, isolated systolic hypertension; and BMI, body mass index. | ||||